4.3 Editorial Material

Antimicrobial peptides: new drugs for bad bugs?

Journal

EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 14, Issue 1, Pages 11-14

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2013.844227

Keywords

antibiotics; antimicrobial peptides; drug-resistant bacteria; peptide design

Funding

  1. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072506] Funding Source: NIH RePORTER
  2. NCATS NIH HHS [UL1 TR000005] Funding Source: Medline
  3. NIDDK NIH HHS [P30 DK072506] Funding Source: Medline

Ask authors/readers for more resources

Antibiotics have been among the most successful classes of therapeutics and have enabled many of modern medicine's greatest advances. However, antibiotic-resistant bacteria are emerging as critical public health threats, with recent accounts of bacterial strains resistant to all approved antibiotics. Antimicrobial peptides (AMPs) are naturally occurring molecules with the potential to serve as the basis for a new class of anti-infectives targeting these difficult-to-treat bacteria. The unique activities and features of AMPs are discussed, with a focus toward the clinical importance of priming the antibiotic pipeline and the role AMPs can fulfill in the future of fighting drug-resistant bacteria.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available